Myriad's GeneSight Psychotropic Genetic Test Improves Depression Therapy In Trial
Executive Summary
Results of a randomized trial presented at the American Psychiatric Association conference show the GeneSight Psychotropic genetic test can improve the treatment of depression by identifying the medications most and least likely to be effective.
You may also be interested in...
August M&A Analysis: Slow Month Highlighted By Unique Technologies
The dog-days of summer produced just a handful of mergers and acquisitions in the medtech sector and no blockbuster deals. However, several companies made smaller deals for innovative products in a range of sectors including IVDs, cardiovascular devices, and ophthalmology.
News We’re Watching: FDA Approves Medtronic's Affera, Roche's CGM Moves Closer To Approval, And More
Medtech Insight's News We're Watching covers medtech industry and research news you may have missed. This week, the Advanced Technologies and Treatments for Diabetes (ATTD) conference in Florence, Italy, included new results from studies of Roche's continuous glucose monitor and Medtronic's 780G insulin pump, Medtronic moved closer to earning FDA approval for its Affera ablation mapping and ablation system, and Linus Health expanded its technology for finding signs of cognitive problems in speech data.
New’s We’re Watching: J&J's Varipulse PFA Earns CE Mark; Labs Create Intravascular Robots; And More
Medtech Insight's News We're Watching highlights some recent business and R&D developments you may have missed. This week, Biosense Webster’s Varipulse PFA platform earned a CE mark; Biosense Webster also announced the start the pivotal IDE study of its Laminar left atrial appendage elimination system; the FDA approved Boston Scientific's Agent paclitaxel-coated balloon and cleared Medtronic's OsteoCool 2.0 bone ablation system; three papers in Science Robotics describe magnetically controlled vascular robots that could go places wires and catheters cannot.